Royalty Pharma plc
NMS: RPRXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Royalty Pharma plc's price action across multiple timeframes using regression channels and statistical scoring.
Get RPRX Z-Score →About Royalty Pharma plc
Healthcare
Biotechnology
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
📊 Fundamental Analysis
Royalty Pharma plc demonstrates exceptional profitability, with a profit margin of 32.4%.
The company recently reported 4.8% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 13.2%, which suggests room for improvement in capital utilization.
At a current price of $47.90, RPRX currently trades near the top of its 52-week range (93%) (Range: $31.58 - $49.06).
💰 Valuation Insight
RPRX is valued broadly in line with the sector at a PE of 26.91. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$27.71B
Trailing P/E
26.91
Forward P/E
8.71
Beta (5Y)
0.39
52W High
$49.06
52W Low
$31.58
Avg Volume
3.58M
Day High
Day Low